CyanVac LLC
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2017-01-01
- Employees
- -
- Market Cap
- -
- Website
- https://www.cyanvacllc.com
Clinical Trials
4
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
A Phase 1 Trial of Intranasal Mumps Virus Vaccines in Healthy Adults
- Conditions
- Mumps
- Interventions
- Biological: CVM150Biological: CVM26Other: Placebo
- First Posted Date
- 2025-05-13
- Last Posted Date
- 2025-06-10
- Lead Sponsor
- CyanVac LLC
- Target Recruit Count
- 60
- Registration Number
- NCT06967181
- Locations
- 🇺🇸
University Of Rochester Medical Center, Rochester, New York, United States
🇺🇸Cincinnati Children's Hospital Medical Center Vaccine Research Center, Cincinnati, Ohio, United States
🇺🇸Coastal Carolina Research Center, North Charleston, South Carolina, United States
A Phase 2b, Randomized, Double-blind, Active-controlled Study of Single Dose CVXGA Intranasal COVID-19 Vaccine in Adults
- Conditions
- COVID-19
- Interventions
- Biological: CVXGA (CVXGA50)Biological: COMIRNATY®
- First Posted Date
- 2024-12-19
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- CyanVac LLC
- Target Recruit Count
- 10016
- Registration Number
- NCT06742281
- Locations
- 🇺🇸
Pinnacle Research Group, LLC, Anniston, Alabama, United States
🇺🇸Velocity Clinical Research, Phoenix, Phoenix, Arizona, United States
🇺🇸Velocity Clinical Research, Chula Vista, Chula Vista, California, United States
A Phase 2 Trial of the Immunogenicity and Safety of CVXGA Intranasal COVID Vaccine in Healthy Adults
- First Posted Date
- 2023-02-21
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- CyanVac LLC
- Target Recruit Count
- 227
- Registration Number
- NCT05736835
- Locations
- 🇺🇸
Velocity Clinical Research, Cedar Park, Texas, United States
🇺🇸University of Rochester, Rochester, New York, United States
🇺🇸Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
Phase 1 Study of Intranasal PIV5 COVID-19 Vaccine Expressing SARS-CoV-2 Spike Protein in Healthy Adults and Adolescents
- Conditions
- Covid19
- First Posted Date
- 2021-07-08
- Last Posted Date
- 2024-02-07
- Lead Sponsor
- CyanVac LLC
- Target Recruit Count
- 72
- Registration Number
- NCT04954287
- Locations
- 🇺🇸
Kentucky Pediatric/ Adult Research, Bardstown, Kentucky, United States
🇺🇸University of Rochester Medical Center, Rochester, New York, United States
🇺🇸Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
News
Blue Lake and CyanVac Report Promising Phase 1 Results for Intranasal COVID-19 Vaccine CVXGA
Blue Lake Biotechnology and CyanVac published full Phase 1 data in Science Advances showing their intranasal COVID-19 vaccine candidate CVXGA demonstrated safety and immunogenicity in 72 healthy subjects aged 12-51 years.
First US Nasal COVID-19 Vaccine Shows 67% Infection Reduction in Phase 1 Trial
CyanVac's CVXGA nasal COVID-19 vaccine demonstrated a 67% reduction in infection risk compared to unvaccinated individuals in the first US-based phase 1 clinical trial.
CyanVac's Intranasal COVID-19 Vaccine Candidate, CVXGA, Enters Phase 2b Trial
CyanVac's CVXGA, an intranasal COVID-19 vaccine, has dosed its first participant in a Phase 2b clinical study.
Blue Lake and CyanVac's Intranasal COVID-19 Vaccine Shows Promise in Phase 2a Trial
Blue Lake and CyanVac reported positive Phase 2a clinical trial data for their intranasal COVID-19 vaccine candidate, CVXGA, demonstrating safety and efficacy.
Blue Lake and CyanVac Present Promising Intranasal Vaccine Data at ISV Annual Congress
Blue Lake Biotechnology and CyanVac presented positive interim Phase 1/2a data for BLB201, an intranasal vaccine candidate against respiratory syncytial virus (RSV), in RSV-seropositive children.